Evofem Biosciences sets Dec. 1, 2026 note maturity in fifth amendment with Adjuvant

Evofem Biosciences, Inc.

Fifth Amendment to the Oct. 14, 2020 Securities Purchase Agreement with Adjuvant Global Health Technology Fund signed Oct. 9, 2026
Notes plus accrued interest now due in full on earliest of Dec. 1, 2026, a Change of Control elected by Adjuvant, or acceleration under Section 8
Notes may not be prepaid before Dec. 1, 2026 without Adjuvant's prior written consent
Section 7.1(f) affirmative covenant deleted in its entirety and replaced with '[Reserved]'
Adjuvant represented it holds a majority of outstanding note balances, constituting the Requisite Purchasers under Section 10.8

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.